Skip to main content
Molecular Therapy logoLink to Molecular Therapy
. 2022 Aug 11;30(9):3095. doi: 10.1016/j.ymthe.2022.07.017

Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in Immunotherapy

Yang Yu, Li Liao, Bingyi Shao, Xiaoxia Su, Yi Shuai, Han Wang, Fengqing Shang, Zhifei Zhou, Deqin Yang , Yan Jin
PMCID: PMC9482016  PMID: 35961307

Main text

(Molecular Therapy 25, 480–493; February 2017)

The authors of this article have reported that some images in Figures 3A, 3D, and 4E have been used in both this article and “Redundant let-7a suppresses the immunomodulatory properties of BMSCs by inhibiting the Fas/FasL system in osteoporosis” (https://doi.org/10.1096/fj.201700885R). An image in Figure 4E was also reused in Figure 6E within the Molecular Therapy article.

FASEB is issuing a correction for “Redundant let-7a suppresses the immunomodulatory properties of BMSCs by inhibiting the Fas/FasL system in osteoporosis.” Molecular Therapy has requested all original data for “Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in Immunotherapy” for review. We are publishing this editorial expression of concern while the editors investigate the issues raised by the authors.


Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES